Results from the first of two pivotal Phase 3 trials were published in Ophthalmology ![]() Food and Drug Administration (FDA) accepted the New Drug Application for NOV03 4 (perfluorohexyloctane), an investigational treatment with a proposed indication of treating the signs and symptoms of dry eye disease associated with Meibomian gland dysfunction PreserVision ® AREDS 2 Formula mini soft gels with OCUSorb ™ in the United States ![]() Project Watson ™ health care products for dogs in the United States Revive ™ custom soft contact lenses in the United StatesĮnhanced Ocuvite ® Adult 50+ eye vitamins with 30 micrograms of vitamin D in the United States XIPERE ®3 (triamcinolone acetonide injectable suspension), a therapy that uses the suprachoroidal space to treat patients suffering from macular edema associated with uveitis, in the United States XIPERE ® has also been filed for regulatory approval in Canadaīiotrue ® Hydration Plus Multi-Purpose Solution in the United States Launched and introduced multiple products across our core segments, including: 16, 2023, in an advisory capacity, where he is working closely with Mr. will become the Lead Independent Director of the Board. Saunders’ appointment as chair of the Board, Thomas W. Papa will step down from his roles as CEO and director. Concurrent with this appointment, and as previously announced, Joseph C. 15, 2023, the Company announced the appointment of Brent Saunders as CEO and chair of the Board of Directors (“Board”), effective March 6, 2023. Papa.īrent Saunders Will Serve as CEO and Chair of the Board of Directors, Effective March 6, 2023 I have known Brent for a long time, and with his long and esteemed track record in the health care industry, he has the right skills and experience to lead Bausch + Lomb at this critical time in our Company’s history,” continued Mr. ![]() “I’m very excited for the future of Bausch + Lomb with Brent Saunders as the incoming CEO and chair of the Board of Directors. “Substantial progress was made in 2022 to complete our full separation from Bausch Health, and due to the dedication and unwavering focus of our employees, I am confident Bausch + Lomb is well-positioned for success as a stand-alone pure-play eye health company.” Additionally, the fourth quarter marked our seventh consecutive quarter of organic growth 1,2, with all three segments growing organically 1,2,” said Joseph C. “Bausch + Lomb delivered another year of strong performance in 2022, growing the business organically 1,2 at a mid-single-digit rate. VAUGHAN, Ontario-( BUSINESS WIRE)-Bausch + Lomb Corporation, (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”, “we” or “our”), a leading global eye health company dedicated to helping people see better to live better, today announced its fourth-quarter and full-year 2022 financial results.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |